← Leaderboards
Alexander B Sigalov
Signablok, Inc.
$7,881,720
Attributed
$8,131,512
Total exposure
17
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,131,512 · 17
By mechanism
R44$4,707,839 · 4
R43$2,768,231 · 11
R61$499,585 · 1
R21$155,857 · 1
Top collaborators
- Andrey Komissarov1 shared
Others in their field
Top investigators on “Macrophage”
- Craig B Thompson · Sloan-Kettering Inst Can Research$41,669,179
- Howard Eliot Gendelman · Children'S Memorial Hospital (Chicago)$41,668,744
- Selwyn M Vickers · University Of Alabama At Birmingham$40,969,055
- Alan A Aderem · University Of Washington$38,969,733
- Alan Richard Tall · Columbia University Health Sciences$38,053,695
- John S Condeelis · Yeshiva University$33,855,255
Research focus
MacrophagePeptidesDoseAnimal ModelIn VivoIn VitroCytokineLigandsLeadMouse ModelMalignant NeoplasmsToxicologyFormulationMacrophage Colony-Stimulating FactorMyeloid CellsInnovationInflammationBaseReceptorDrug KineticsAnimalsHalf-LifeComplexInhibitor/Antagonist
Grant awards (21)
First-in-class TREM-1 inhibitors for neovascular retinal diseases$830,491
R44 · FY2025 · EY · contact PI
Concurrent targeting of inflammation and the inhibition of the fibrinolytic system to increase the efficacy of empyema treatment$499,585
R61 · FY2025 · HL
TREM-1 therapy for the treatment of empyema$457,954
R43 · FY2025 · HL · contact PI
Novel medical countermeasure to mitigate potentially lethal acute radiation syndrome$155,857
R21 · FY2025 · AI · contact PI
First-in-class TREM-1 inhibitors for neovascular retinal diseases$278,127
R44 · FY2023 · EY · contact PI
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome$272,741
R43 · FY2023 · HL · contact PI
First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer$1,198,246
R44 · FY2020 · CA · contact PI
TREM-1 therapy for rheumatoid arthritis$258,603
R44 · FY2020 · AR · contact PI
TREM-1 inhibitor for the treatment of scleroderma$249,601
R43 · FY2020 · AR · contact PI
First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer$799,560
R44 · FY2019 · CA · contact PI
First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer$2,084
R43 · FY2019 · CA · contact PI
Development of first-in-class TREM-1 inhibitors for neovascular retinal diseases$226,223
R43 · FY2018 · EY · contact PI
Novel TREM-1 targeting therapies for sepsis$224,996
R43 · FY2018 · GM · contact PI
First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer$224,672
R43 · FY2017 · CA · contact PI
Treatment of alcoholic liver disease with novel targeted inhibitors$223,443
R43 · FY2016 · AA · contact PI
Multifunctional nanoformulations for diagnostic imaging of atherosclerosis$673,165
R44 · FY2015 · HL · contact PI
Development of novel targeted agents in pancreatic cancer$219,937
R43 · FY2015 · CA · contact PI
Multifunctional nanoformulations for diagnostic imaging of atherosclerosis$669,647
R44 · FY2014 · HL · contact PI
Novel mechanism-based targeted approach to rheumatoid arthritis$223,013
R43 · FY2014 · AR · contact PI
Multifunctional nanoformulations for diagnostic imaging of atherosclerosis$221,829
R43 · FY2012 · HL · contact PI
Development of novel targeted agents in lung cancer$221,738
R43 · FY2012 · CA · contact PI